IBBM   21076
Unidad Ejecutora - UE
congresos y reuniones científicas
Outer membrane vesicles as an attractive candidate for pertussis vaccine
Simposio; 11 th Internation Bordetella Symposium; 2016
<!-- /* Font Definitions */@font-face{font-family:Times;panose-1:2 0 5 0 0 0 0 0 0 0;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:3 0 0 0 1 0;}@font-face{font-family:"Cambria Math";panose-1:2 4 5 3 5 4 6 3 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face{font-family:Cambria;panose-1:2 4 5 3 5 4 6 3 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1073743103 0 0 415 0;}@font-face{font-family:"MS ??";panose-1:0 0 0 0 0 0 0 0 0 0;mso-font-alt:"Arial Unicode MS";mso-font-charset:128;mso-generic-font-family:auto;mso-font-format:other;mso-font-pitch:variable;mso-font-signature:1 134676480 16 0 131072 0;} /* Style Definitions */p.MsoNormal, li.MsoNormal, div.MsoNormal{mso-style-unhide:no;mso-style-qformat:yes;mso-style-parent:"";margin:0cm;margin-bottom:.0001pt;mso-pagination:widow-orphan;font-size:12.0pt;font-family:Cambria;mso-fareast-font-family:"MS ??";mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US;}.MsoChpDefault{mso-style-type:export-only;mso-default-props:yes;font-size:11.0pt;mso-ansi-font-size:11.0pt;mso-bidi-font-size:11.0pt;font-family:Cambria;mso-ascii-font-family:Cambria;mso-fareast-font-family:"MS ??";mso-hansi-font-family:Cambria;mso-ansi-language:ES;mso-fareast-language:ES;}@page WordSection1{size:595.0pt 842.0pt;margin:72.0pt 90.0pt 72.0pt 90.0pt;mso-header-margin:35.4pt;mso-footer-margin:35.4pt;mso-paper-source:0;}div.WordSection1{page:WordSection1;}-->Outer membrane vesicles as anattractive candidate for pertussis vaccineHozbor, D. Laboratorio VacSal. Instituto de Biotecnolog√≠a yBiolog√≠a Molecular (IBBM). Facultad de Ciencias Exactas. Universidad Nacionalde La Plata. CCT-CONICET La Plata. Calles 50 y 115. 1900. La Plata. Argentina. Gram-negative bacterianaturally release lipid bilayer vesicles from the outer membrane. Outermembrane vesicles (OMVs)range in size from approximately 20-200 nanometers in diameter and enclose manynative bacterial antigens in the spherical particles. The vesicles function indiverse roles including facilitation of the infection progression. Due to theirimmunogenic properties, self-adjuvanticity and ability to be taken up bymammalian cells, OMVs (hereinafter also referred to as nanoparticles) areattractive candidates as vaccine delivery platforms. We have developed a newvaccine against pertussis based on outer membrane vesicle, which have beenshown to be safe and to induce protection in mice. Furthermore, it elicits aprotective immune response with a mixed Th1, Th2 and Th17 profile and alsoinduces a robust antibody response. Interestingly OMVs-raised antibodies suchas those induced by commercial whole cell vaccine and acellular vaccines (aP),which contribute to induce protection against B. pertussis infection. We have characterized the composition ofthe pertussis nanoparticles, finding > 40 protein components, mostlymembrane-bound proteins. The presence of a high number of immunogens in thevaccine formulation is important since this may avoid the excessive selectivepressure conferred by a single or a few protective vaccine antigens. OurOMV-based vaccine exhibits adequate protection capacity against different B. pertussis genetic background includingthose not expressing the virulence factor pertactin (PRN) that is also includedin commercial vaccines. Our formulation also is attractive economically, whichis critical for its use in developing countries. It is estimated that the finalcost per dose is less than that of existing aP formulations based on severalpurified protein immunogens, which impacts on the final cost of the vaccine. Inour case a single process step is necessary for the production of each B. pertussis and B. parapertussis nanoparticle.